The factor Xa inhibitor apixaban is one of the novel anticoagulants to emerge as alternatives
to long‐standing standards of care that include low‐molecular‐weight heparin and warfarin …

The direct factor Xa inhibitor apixaban (Eliquis®) has predictable pharmacodynamics and
pharmacokinetics and does not require routine anticoagulation monitoring. This article …

Stroke prevention in atrial fibrillation (AF) has been challenging over decades, mostly due to
a number of difficulties associated with oral vitamin K antagonists (VKAs), which have been …

Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with
vitamin K antagonists (VKAs). Vitamin K antagonist use is limited, in part, by the high …

Atrial fibrillation is a common, costly and morbid cardiovascular arrhythmia. Stroke
prevention remains the mainstay of treatment for atrial fibrillation, and the recent advent of …

Atrial fibrillation (AF) is a common cardiac arrhythmia, especially in the elderly population. It
is associated with cardioembolic complications, particularly strokes, resulting in severe …

Background—Apixaban is approved for the prevention of stroke and systemic embolism in
patients with nonvalvular atrial fibrillation. However, the Apixaban for Reduction in Stroke …

Background Vitamin K antagonists are highly effective in preventing stroke in patients with
atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa …

Background Patients with atrial fibrillation who are vitamin K antagonist (VKA)-naive may
have a higher risk of thrombosis and/or bleeding than VKA-experienced patients. Methods …

Conventional anticoagulant therapies can significantly reduce the risk of stroke and related
complications in patients with atrial fibrillation (AF). Classic oral anticoagulants based on …